PADI4 and breast carcinoma: Another study has uncovered the inhibition of immune cytotoxicity by NETs via immune cell-target cell contact impairment and inhibition of NETosis by pharmacologically suppressing PAD4 augments tumor sensitivity to PD-1 + CTLA-4 dual checkpoint blockade in a syngeneic mouse model of breast cancer [9].